Sorbent's lead heart failure product shows Phase II promise

The private US biopharmaceutical company Sorbent Therapeutics has presented promising Phase II data for its lead drug candidate, CLP1001, at a late-breaking clinical trials session at the ESC Heart Failure Congress in Belgrade, Serbia.

The private US biopharmaceutical company Sorbent Therapeutics has presented promising Phase II data for its lead drug candidate, CLP1001, at a late-breaking clinical trials session at the ESC Heart Failure Congress in Belgrade, Serbia.

The non-absorbed cross-linked polyelectrolyte polymer is designed to remove potassium, sodium and fluid from the gastrointestinal tract to reduce fluid...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category